MedTrace Logo

Multicenter Study on Fibrotic Valvular Heart Disease in Patients With Parkinson's Disease Treated With Dopamine Agonists

NCT00196898 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2012-03-19

No results posted yet for this study

Summary

Fibrotic valvular heart diseases are known as rare complications of long-time therapy of Parkinson's disease with ergot-derivatives including some ergot-dopamine agonists. The aim of this study is to assess the incidence of valvular heart disease, which may be an ergot-drug agonists side-effect or an overall complication of all dopamine agonists. Incidence, prevalence and addiction of dose or intake duration are not known so far. The reversibility of the changes is unknown too. To answer these questions the present study is designed as a cross sectional study followed by a 2 year follow-up prospective cohort study.

Conditions

Sponsors & Collaborators

  • Competence Network on Parkinson's Disease

    collaborator OTHER

  • German Parkinson Study Group (GPS)

    lead OTHER

Principal Investigators

  • Wolfgang Oertel, Prof. Dr. · Universitätsklinikum Marburg und Gießen

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-03-31
Completion
2013-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00196898 on ClinicalTrials.gov